Overview
SCIENTIFIC SCORE
Moderately Effective
Based on 11 Researches
8.1
USERS' SCORE
Good
Based on 3 Reviews
8.4
Supplement Facts
Serving Size: 1 tbsp (15 ml)
Amount Per Serving
%DV
Calories
120
Total Fat
14 g
18%
Saturated Fat
2.5 g
13%
Polyunsaturated Fat
8 g
Monounsaturated Fat
2 g
Sodium
0 mg
0%
Total Carbohydrate
0 g
0%
Protein
0 g
Vitamin E
20 mg
130%
Top Medical Research Studies
9
We investigated the potential of a specific protein, PTGFRN, as a new target for chimeric antigen receptor (CAR) T-cell therapy aimed at treating glioblastoma, a type of aggressive brain tumor. Our study involved creating a library of monoclonal antibodies (mAbs) that would ideally react with cancer cells from patients while sparing healthy brain cells. Through this process, we identified mAbs that successfully targeted tumor cells in resected tissues from patients with glioblastoma.
Among the promising candidates, we focused on the mAb called 5E17, which was found to interact with tumor cells from six out of seven patients but not with any non-cancerous brain cells. We discovered that PTGFRN is the antigen recognized by this antibody. When we generated CAR-T cells based on 5E17, these engineered cells showed significant activity, producing beneficial cytokines and displaying effective tumor cell killing in lab tests. Further trials in mice injected with human-derived glioblastoma tissues demonstrated the ability of 5E17-CAR-T cells to fight tumors in a living organism.
This research suggests that PTGFRN could be a fruitful target for CAR-T cell treatments in glioblastoma patients. However, we need to approach future studies with caution to carefully evaluate any potential off-target effects this approach may have on normal tissues.
Among the promising candidates, we focused on the mAb called 5E17, which was found to interact with tumor cells from six out of seven patients but not with any non-cancerous brain cells. We discovered that PTGFRN is the antigen recognized by this antibody. When we generated CAR-T cells based on 5E17, these engineered cells showed significant activity, producing beneficial cytokines and displaying effective tumor cell killing in lab tests. Further trials in mice injected with human-derived glioblastoma tissues demonstrated the ability of 5E17-CAR-T cells to fight tumors in a living organism.
This research suggests that PTGFRN could be a fruitful target for CAR-T cell treatments in glioblastoma patients. However, we need to approach future studies with caution to carefully evaluate any potential off-target effects this approach may have on normal tissues.
9
We investigated a promising method to combat central nervous system lymphoma (CNSL) using protein-encapsulated exosomes. By utilizing human adipose-derived stem cells modified with a lentiviral vector that encodes anti-CD19, we created a targeted delivery system to enhance the permeability of medication across the blood-brain barrier (BBB).
The focus was on reducing the high doses of methotrexate typically required while maintaining its effectiveness against CNSL. To achieve this, we loaded methotrexate into the anti-CD19 exosomes and tested their ability to penetrate the BBB using a specialized model. Our findings used MRI imaging to evaluate how well the exosomes worked in real-life scenarios involving brain tumors.
Additionally, we monitored the spread of the exosomes within the brain and measured drug concentration in cerebrospinal fluid. We also looked into the protective effects of the proteins from the exosomes on neurons in brain models of CNSL. Our comprehensive approach demonstrated that this novel exosome-based delivery method allows for targeted treatment while minimizing adverse effects on organs like the liver and kidneys.
The results suggest that anti-CD19-exosome methotrexate treatment is a powerful approach for addressing CNSL, paving the way for more effective and safer therapeutic strategies.
The focus was on reducing the high doses of methotrexate typically required while maintaining its effectiveness against CNSL. To achieve this, we loaded methotrexate into the anti-CD19 exosomes and tested their ability to penetrate the BBB using a specialized model. Our findings used MRI imaging to evaluate how well the exosomes worked in real-life scenarios involving brain tumors.
Additionally, we monitored the spread of the exosomes within the brain and measured drug concentration in cerebrospinal fluid. We also looked into the protective effects of the proteins from the exosomes on neurons in brain models of CNSL. Our comprehensive approach demonstrated that this novel exosome-based delivery method allows for targeted treatment while minimizing adverse effects on organs like the liver and kidneys.
The results suggest that anti-CD19-exosome methotrexate treatment is a powerful approach for addressing CNSL, paving the way for more effective and safer therapeutic strategies.
9
We explored the role of a protein called Embigin (EMB) in the progression of glioblastoma multiforme (GBM), an aggressive brain tumor. Our research focused on whether EMB contributes to tumor growth and how effective Ganxintriol A, a natural compound derived from traditional Chinese medicine, could be in treating this condition.
Through various laboratory tests and bioinformatics analysis, we discovered that EMB is found in high levels in GBM, which is linked to poorer outcomes for patients. When we increased EMB levels in brain cancer cells, we noticed that the cells grew faster. Conversely, reducing EMB levels slowed down the tumor progression. The research also revealed that EMB boosts processes that enable cells to invade surrounding tissues and generate energy, helping tumors grow while maintaining a balance of antioxidants in the cells.
Encouragingly, treatment with Ganxintriol A showed promising results. It effectively decreased EMB levels and hindered the growth of GBM in both lab settings and animal models. This suggests that Ganxintriol A could be a worthwhile option for treating glioblastoma by targeting EMB.
All in all, our findings position EMB as not just a biomarker of GBM but also a potential driver of its progression. We have also identified Ganxintriol A as a valuable therapeutic candidate worth further exploration in the fight against this challenging brain cancer.
Through various laboratory tests and bioinformatics analysis, we discovered that EMB is found in high levels in GBM, which is linked to poorer outcomes for patients. When we increased EMB levels in brain cancer cells, we noticed that the cells grew faster. Conversely, reducing EMB levels slowed down the tumor progression. The research also revealed that EMB boosts processes that enable cells to invade surrounding tissues and generate energy, helping tumors grow while maintaining a balance of antioxidants in the cells.
Encouragingly, treatment with Ganxintriol A showed promising results. It effectively decreased EMB levels and hindered the growth of GBM in both lab settings and animal models. This suggests that Ganxintriol A could be a worthwhile option for treating glioblastoma by targeting EMB.
All in all, our findings position EMB as not just a biomarker of GBM but also a potential driver of its progression. We have also identified Ganxintriol A as a valuable therapeutic candidate worth further exploration in the fight against this challenging brain cancer.
Most Useful Reviews
9
Boosts brain health
1 people found this helpful
Excellent, I use it all the time. The ingredients include wheat germ oil, which is not widely known. At 27 years old, I've found the oil’s thickness to be high and the packaging sufficient. The benefits align exactly with the claims. Omega is incredibly beneficial for brain health. I applied it to my hair, and it greatly improved dryness and frizz, enhancing its overall condition. It's also suitable for those with cholesterol issues. I honestly recommend it; it helps in removing melasma, spots, dark circles, and skin marks, and it pairs well with other oils.
7.5
Supports brain health
I take this for its Vitamin E content, which features a broader spectrum of vitamin Es compared to standard supplements. It's excellent for brain health.
7.5
Nourishes brain function
Wheat germ oil is a nutrient-dense and versatile product, replete with vitamin E, omega fatty acids, and other essential nutrients offering numerous health benefits. It promotes skin health, aids in cholesterol reduction, and supports hair health. The oil's rich omega-3 and omega-6 fatty acids contribute to brain function, combat inflammation, and encourage overall well-being. Quality and packaging play a significant role in nutrient preservation, so opt for cold-pressed, high-quality options in dark bottles to ensure freshness. Wheat germ oil is an excellent choice for enhancing skin, hair, and heart health.
Medical Researches
SCIENTIFIC SCORE
Moderately Effective
Based on 11 Researches
8.1
- All Researches
9
We explored the role of interleukin-19 (IL-19) in glioblastoma multiforme (GBM), a notoriously aggressive brain tumor. The study combined clinical data and genomic analysis to understand how IL-19 contributes to the tumor's immunosuppressive environment and its overall impact on patient survival.
By blocking IL-19 in mouse models, we observed significant tumor progression inhibition, even in cases where tumors are resistant to traditional chemotherapy. The research showed that this blockade reprograms the immune microenvironment, enhancing the presence of beneficial immune cells while decreasing those that support tumor growth.
Importantly, our findings revealed that IL-19 is part of a signaling pathway that promotes invasion and migration in GBM cells. We also developed a novel system using nanoparticles designed to target areas expressing IL-19 in brain tumors, which demonstrated promising results in visualizing these tumor regions with MRI.
Overall, our study suggests that targeting IL-19 could be a viable strategy not just for imaging but also for enhancing treatment efficacy against chemoresistant GBM cells.
By blocking IL-19 in mouse models, we observed significant tumor progression inhibition, even in cases where tumors are resistant to traditional chemotherapy. The research showed that this blockade reprograms the immune microenvironment, enhancing the presence of beneficial immune cells while decreasing those that support tumor growth.
Importantly, our findings revealed that IL-19 is part of a signaling pathway that promotes invasion and migration in GBM cells. We also developed a novel system using nanoparticles designed to target areas expressing IL-19 in brain tumors, which demonstrated promising results in visualizing these tumor regions with MRI.
Overall, our study suggests that targeting IL-19 could be a viable strategy not just for imaging but also for enhancing treatment efficacy against chemoresistant GBM cells.
9
We examined how clofazimine, a medication known for inhibiting a specific signaling pathway, could enhance treatments for glioblastoma, a highly aggressive brain tumor. Our investigation revealed that clofazimine not only hindered cancer cell growth and invasion, but it also triggered cell death by targeting the Wnt6 signaling pathway. This led to reduced levels of a protein called PD-L1, which is often involved in helping tumors evade the immune system.
Moreover, when we combined clofazimine with anti-PD-1 therapy, the results were impressive. We observed notable reductions in tumor size and less invasion into the brain, along with a longer survival rate in mouse models with glioblastoma. This combination therapy seemed to help the immune system fight back against the tumor by increasing the presence of cytotoxic CD8 T cells and decreasing regulatory T cells, which typically suppress immune responses.
Our findings suggest that clofazimine has the potential to enhance anti-PD-1 immunotherapy by not only impacting tumor biology but also reshaping the immune landscape around the tumor. While these results show great promise, further clinical research is essential to better understand how effective and safe this combined approach could be for patients with glioblastoma.
Moreover, when we combined clofazimine with anti-PD-1 therapy, the results were impressive. We observed notable reductions in tumor size and less invasion into the brain, along with a longer survival rate in mouse models with glioblastoma. This combination therapy seemed to help the immune system fight back against the tumor by increasing the presence of cytotoxic CD8 T cells and decreasing regulatory T cells, which typically suppress immune responses.
Our findings suggest that clofazimine has the potential to enhance anti-PD-1 immunotherapy by not only impacting tumor biology but also reshaping the immune landscape around the tumor. While these results show great promise, further clinical research is essential to better understand how effective and safe this combined approach could be for patients with glioblastoma.
9
We investigated the potential of a specific protein, PTGFRN, as a new target for chimeric antigen receptor (CAR) T-cell therapy aimed at treating glioblastoma, a type of aggressive brain tumor. Our study involved creating a library of monoclonal antibodies (mAbs) that would ideally react with cancer cells from patients while sparing healthy brain cells. Through this process, we identified mAbs that successfully targeted tumor cells in resected tissues from patients with glioblastoma.
Among the promising candidates, we focused on the mAb called 5E17, which was found to interact with tumor cells from six out of seven patients but not with any non-cancerous brain cells. We discovered that PTGFRN is the antigen recognized by this antibody. When we generated CAR-T cells based on 5E17, these engineered cells showed significant activity, producing beneficial cytokines and displaying effective tumor cell killing in lab tests. Further trials in mice injected with human-derived glioblastoma tissues demonstrated the ability of 5E17-CAR-T cells to fight tumors in a living organism.
This research suggests that PTGFRN could be a fruitful target for CAR-T cell treatments in glioblastoma patients. However, we need to approach future studies with caution to carefully evaluate any potential off-target effects this approach may have on normal tissues.
Among the promising candidates, we focused on the mAb called 5E17, which was found to interact with tumor cells from six out of seven patients but not with any non-cancerous brain cells. We discovered that PTGFRN is the antigen recognized by this antibody. When we generated CAR-T cells based on 5E17, these engineered cells showed significant activity, producing beneficial cytokines and displaying effective tumor cell killing in lab tests. Further trials in mice injected with human-derived glioblastoma tissues demonstrated the ability of 5E17-CAR-T cells to fight tumors in a living organism.
This research suggests that PTGFRN could be a fruitful target for CAR-T cell treatments in glioblastoma patients. However, we need to approach future studies with caution to carefully evaluate any potential off-target effects this approach may have on normal tissues.
9
We investigated a promising method to combat central nervous system lymphoma (CNSL) using protein-encapsulated exosomes. By utilizing human adipose-derived stem cells modified with a lentiviral vector that encodes anti-CD19, we created a targeted delivery system to enhance the permeability of medication across the blood-brain barrier (BBB).
The focus was on reducing the high doses of methotrexate typically required while maintaining its effectiveness against CNSL. To achieve this, we loaded methotrexate into the anti-CD19 exosomes and tested their ability to penetrate the BBB using a specialized model. Our findings used MRI imaging to evaluate how well the exosomes worked in real-life scenarios involving brain tumors.
Additionally, we monitored the spread of the exosomes within the brain and measured drug concentration in cerebrospinal fluid. We also looked into the protective effects of the proteins from the exosomes on neurons in brain models of CNSL. Our comprehensive approach demonstrated that this novel exosome-based delivery method allows for targeted treatment while minimizing adverse effects on organs like the liver and kidneys.
The results suggest that anti-CD19-exosome methotrexate treatment is a powerful approach for addressing CNSL, paving the way for more effective and safer therapeutic strategies.
The focus was on reducing the high doses of methotrexate typically required while maintaining its effectiveness against CNSL. To achieve this, we loaded methotrexate into the anti-CD19 exosomes and tested their ability to penetrate the BBB using a specialized model. Our findings used MRI imaging to evaluate how well the exosomes worked in real-life scenarios involving brain tumors.
Additionally, we monitored the spread of the exosomes within the brain and measured drug concentration in cerebrospinal fluid. We also looked into the protective effects of the proteins from the exosomes on neurons in brain models of CNSL. Our comprehensive approach demonstrated that this novel exosome-based delivery method allows for targeted treatment while minimizing adverse effects on organs like the liver and kidneys.
The results suggest that anti-CD19-exosome methotrexate treatment is a powerful approach for addressing CNSL, paving the way for more effective and safer therapeutic strategies.
9
We explored the relationship between a specific protein called GOLPH3L and its effects on glioblastoma (GBM), a challenging brain tumor. Our focus was on understanding how GOLPH3L interacts with another crucial protein, STING, in patients who are resistant to standard radiotherapy (RT). We found that in these resistant tumors, GOLPH3L levels were high, contributing to an immunosuppressive environment that hinders effective treatment.
Importantly, we discovered that when GOLPH3L was genetically disabled in the resistant GBM cells, it boosted the body's anti-tumor immune response. This breakthrough suggests that targeting GOLPH3L could potentially help overcome resistance to RT, making the treatment more effective.
We also identified a small molecule inhibitor of GOLPH3L, known as vitamin B5 calcium (VB5). This compound improved the effectiveness of RT and immune checkpoint therapies in mouse models. When we looked at clinical data, patients with GBM who received VB5 showed better responses to their treatments. Thus, modifying the tumor immune environment by focusing on GOLPH3L presents a promising strategy for enhancing glioblastoma therapies.
Importantly, we discovered that when GOLPH3L was genetically disabled in the resistant GBM cells, it boosted the body's anti-tumor immune response. This breakthrough suggests that targeting GOLPH3L could potentially help overcome resistance to RT, making the treatment more effective.
We also identified a small molecule inhibitor of GOLPH3L, known as vitamin B5 calcium (VB5). This compound improved the effectiveness of RT and immune checkpoint therapies in mouse models. When we looked at clinical data, patients with GBM who received VB5 showed better responses to their treatments. Thus, modifying the tumor immune environment by focusing on GOLPH3L presents a promising strategy for enhancing glioblastoma therapies.
User Reviews
USERS' SCORE
Good
Based on 3 Reviews
8.4
- All Reviews
- Positive Reviews
- Negative Reviews
9
Boosts brain health
1 people found this helpful
Excellent, I use it all the time. The ingredients include wheat germ oil, which is not widely known. At 27 years old, I've found the oil’s thickness to be high and the packaging sufficient. The benefits align exactly with the claims. Omega is incredibly beneficial for brain health. I applied it to my hair, and it greatly improved dryness and frizz, enhancing its overall condition. It's also suitable for those with cholesterol issues. I honestly recommend it; it helps in removing melasma, spots, dark circles, and skin marks, and it pairs well with other oils.
7.5
Supports brain health
I take this for its Vitamin E content, which features a broader spectrum of vitamin Es compared to standard supplements. It's excellent for brain health.
7.5
Nourishes brain function
Wheat germ oil is a nutrient-dense and versatile product, replete with vitamin E, omega fatty acids, and other essential nutrients offering numerous health benefits. It promotes skin health, aids in cholesterol reduction, and supports hair health. The oil's rich omega-3 and omega-6 fatty acids contribute to brain function, combat inflammation, and encourage overall well-being. Quality and packaging play a significant role in nutrient preservation, so opt for cold-pressed, high-quality options in dark bottles to ensure freshness. Wheat germ oil is an excellent choice for enhancing skin, hair, and heart health.
Frequently Asked Questions
9
Boosts brain health
1 people found this helpful
Excellent, I use it all the time. The ingredients include wheat germ oil, which is not widely known. At 27 years old, I've found the oil’s thickness to be high and the packaging sufficient. The benefits align exactly with the claims. Omega is incredibly beneficial for brain health. I applied it to my hair, and it greatly improved dryness and frizz, enhancing its overall condition. It's also suitable for those with cholesterol issues. I honestly recommend it; it helps in removing melasma, spots, dark circles, and skin marks, and it pairs well with other oils.
7.5
Nourishes brain function
Wheat germ oil is a nutrient-dense and versatile product, replete with vitamin E, omega fatty acids, and other essential nutrients offering numerous health benefits. It promotes skin health, aids in cholesterol reduction, and supports hair health. The oil's rich omega-3 and omega-6 fatty acids contribute to brain function, combat inflammation, and encourage overall well-being. Quality and packaging play a significant role in nutrient preservation, so opt for cold-pressed, high-quality options in dark bottles to ensure freshness. Wheat germ oil is an excellent choice for enhancing skin, hair, and heart health.
7.5
Supports brain health
I take this for its Vitamin E content, which features a broader spectrum of vitamin Es compared to standard supplements. It's excellent for brain health.
9
We explored the role of interleukin-19 (IL-19) in glioblastoma multiforme (GBM), a notoriously aggressive brain tumor. The study combined clinical data and genomic analysis to understand how IL-19 contributes to the tumor's immunosuppressive environment and its overall impact on patient survival.
By blocking IL-19 in mouse models, we observed significant tumor progression inhibition, even in cases where tumors are resistant to traditional chemotherapy. The research showed that this blockade reprograms the immune microenvironment, enhancing the presence of beneficial immune cells while decreasing those that support tumor growth.
Importantly, our findings revealed that IL-19 is part of a signaling pathway that promotes invasion and migration in GBM cells. We also developed a novel system using nanoparticles designed to target areas expressing IL-19 in brain tumors, which demonstrated promising results in visualizing these tumor regions with MRI.
Overall, our study suggests that targeting IL-19 could be a viable strategy not just for imaging but also for enhancing treatment efficacy against chemoresistant GBM cells.
By blocking IL-19 in mouse models, we observed significant tumor progression inhibition, even in cases where tumors are resistant to traditional chemotherapy. The research showed that this blockade reprograms the immune microenvironment, enhancing the presence of beneficial immune cells while decreasing those that support tumor growth.
Importantly, our findings revealed that IL-19 is part of a signaling pathway that promotes invasion and migration in GBM cells. We also developed a novel system using nanoparticles designed to target areas expressing IL-19 in brain tumors, which demonstrated promising results in visualizing these tumor regions with MRI.
Overall, our study suggests that targeting IL-19 could be a viable strategy not just for imaging but also for enhancing treatment efficacy against chemoresistant GBM cells.
8
We explored how the natural compound Celastrol could impact glioblastoma, a notoriously challenging type of brain tumor. The study combined cell-based experiments with animal models to understand whether Celastrol could influence mitochondrial dynamics, which are crucial for cell function.
By examining U251, LN229, and U87-MG glioblastoma cells, we found that Celastrol triggers mitochondrial fission, leading to some dysfunction in the cells. This disruption appears to be due to decreased levels of a protein called mitofusin-1, which is necessary for maintaining the health of mitochondria.
Further tests revealed that Celastrol raised oxidative stress levels and lowered the mitochondrial membrane potential while decreasing expression markers associated with cell proliferation. This suggests that Celastrol's effects may slow down tumor growth in glioblastoma.
Overall, our findings propose that Celastrol may be repurposed as a potential treatment targeting mitochondrial dynamics in glioblastoma, needing more in-depth investigation to confirm its therapeutic effectiveness.
By examining U251, LN229, and U87-MG glioblastoma cells, we found that Celastrol triggers mitochondrial fission, leading to some dysfunction in the cells. This disruption appears to be due to decreased levels of a protein called mitofusin-1, which is necessary for maintaining the health of mitochondria.
Further tests revealed that Celastrol raised oxidative stress levels and lowered the mitochondrial membrane potential while decreasing expression markers associated with cell proliferation. This suggests that Celastrol's effects may slow down tumor growth in glioblastoma.
Overall, our findings propose that Celastrol may be repurposed as a potential treatment targeting mitochondrial dynamics in glioblastoma, needing more in-depth investigation to confirm its therapeutic effectiveness.
9
We investigated the potential of a specific protein, PTGFRN, as a new target for chimeric antigen receptor (CAR) T-cell therapy aimed at treating glioblastoma, a type of aggressive brain tumor. Our study involved creating a library of monoclonal antibodies (mAbs) that would ideally react with cancer cells from patients while sparing healthy brain cells. Through this process, we identified mAbs that successfully targeted tumor cells in resected tissues from patients with glioblastoma.
Among the promising candidates, we focused on the mAb called 5E17, which was found to interact with tumor cells from six out of seven patients but not with any non-cancerous brain cells. We discovered that PTGFRN is the antigen recognized by this antibody. When we generated CAR-T cells based on 5E17, these engineered cells showed significant activity, producing beneficial cytokines and displaying effective tumor cell killing in lab tests. Further trials in mice injected with human-derived glioblastoma tissues demonstrated the ability of 5E17-CAR-T cells to fight tumors in a living organism.
This research suggests that PTGFRN could be a fruitful target for CAR-T cell treatments in glioblastoma patients. However, we need to approach future studies with caution to carefully evaluate any potential off-target effects this approach may have on normal tissues.
Among the promising candidates, we focused on the mAb called 5E17, which was found to interact with tumor cells from six out of seven patients but not with any non-cancerous brain cells. We discovered that PTGFRN is the antigen recognized by this antibody. When we generated CAR-T cells based on 5E17, these engineered cells showed significant activity, producing beneficial cytokines and displaying effective tumor cell killing in lab tests. Further trials in mice injected with human-derived glioblastoma tissues demonstrated the ability of 5E17-CAR-T cells to fight tumors in a living organism.
This research suggests that PTGFRN could be a fruitful target for CAR-T cell treatments in glioblastoma patients. However, we need to approach future studies with caution to carefully evaluate any potential off-target effects this approach may have on normal tissues.
9
We examined how clofazimine, a medication known for inhibiting a specific signaling pathway, could enhance treatments for glioblastoma, a highly aggressive brain tumor. Our investigation revealed that clofazimine not only hindered cancer cell growth and invasion, but it also triggered cell death by targeting the Wnt6 signaling pathway. This led to reduced levels of a protein called PD-L1, which is often involved in helping tumors evade the immune system.
Moreover, when we combined clofazimine with anti-PD-1 therapy, the results were impressive. We observed notable reductions in tumor size and less invasion into the brain, along with a longer survival rate in mouse models with glioblastoma. This combination therapy seemed to help the immune system fight back against the tumor by increasing the presence of cytotoxic CD8 T cells and decreasing regulatory T cells, which typically suppress immune responses.
Our findings suggest that clofazimine has the potential to enhance anti-PD-1 immunotherapy by not only impacting tumor biology but also reshaping the immune landscape around the tumor. While these results show great promise, further clinical research is essential to better understand how effective and safe this combined approach could be for patients with glioblastoma.
Moreover, when we combined clofazimine with anti-PD-1 therapy, the results were impressive. We observed notable reductions in tumor size and less invasion into the brain, along with a longer survival rate in mouse models with glioblastoma. This combination therapy seemed to help the immune system fight back against the tumor by increasing the presence of cytotoxic CD8 T cells and decreasing regulatory T cells, which typically suppress immune responses.
Our findings suggest that clofazimine has the potential to enhance anti-PD-1 immunotherapy by not only impacting tumor biology but also reshaping the immune landscape around the tumor. While these results show great promise, further clinical research is essential to better understand how effective and safe this combined approach could be for patients with glioblastoma.
References
- Lee GA, Hsu JB, Chang YW, Hsieh LC, Li YT, et al. IL-19 as a promising theranostic target to reprogram the glioblastoma immunosuppressive microenvironment. J Biomed Sci. 2025;32:34. doi:10.1186/s12929-025-01126-w
- Carstam L, Vecchio TG, Lyczak M, Åberg H, Jakola AS, et al. Antisecretory factor for treatment of peritumoral edema in glioblastoma patients. Acta Neurochir (Wien). 2025;167:64. doi:10.1007/s00701-025-06481-z
- Zhao Y, Song Y, Li W, Wu J, Zhao Z, et al. Clofazimine enhances anti-PD-1 immunotherapy in glioblastoma by inhibiting Wnt6 signaling and modulating the tumor immune microenvironment. Cancer Immunol Immunother. 2025;74:137. doi:10.1007/s00262-025-03994-5
- Liang L, Lv W, Cheng G, Gao M, Sun J, et al. Impact of celastrol on mitochondrial dynamics and proliferation in glioblastoma. BMC Cancer. 2025;25:412. doi:10.1186/s12885-025-13733-9
- Wei R, Shi X, Qiu W, Yang M, Chen Y, et al. ATXN3 deubiquitinates ZEB1 and facilitates epithelial-mesenchymal transition in glioblastoma. Sci Rep. 2025;15:7868. doi:10.1038/s41598-025-92317-w
- Kuroda H, Kijima N, Tachi T, Ikeda S, Murakami K, et al. Prostaglandin F2 receptor negative regulator as a potential target for chimeric antigen receptor-T cell therapy for glioblastoma. Cancer Immunol Immunother. 2025;74:136. doi:10.1007/s00262-025-03979-4
- Zhao M, Li Q, Chai Y, Rong R, He L, et al. An anti-CD19-exosome delivery system navigates the blood-brain barrier for targeting of central nervous system lymphoma. J Nanobiotechnology. 2025;23:173. doi:10.1186/s12951-025-03238-9
- Sun S, Qian S, Wang R, Zhao M, Li R, et al. Targeting GOLPH3L improves glioblastoma radiotherapy by regulating STING-NLRP3-mediated tumor immune microenvironment reprogramming. Sci Transl Med. 2025;17:eado0020. doi:10.1126/scitranslmed.ado0020
- Cheng B, Liu J, Gao L, Zhu Z, Yang Y, et al. EMB-driven glioblastoma multiforme progression via the MCT4/GPX3 axis: therapeutic inhibition by Ganxintriol A. J Transl Med. 2025;23:272. doi:10.1186/s12967-025-06290-z
- Chien YC, Wu JY, Liu LC, Yu YL. Capsanthin inhibits migration and reduces N-linked glycosylation of PD-L1 via the EZH2-PD-L1 axis in triple-negative breast cancer brain metastasis. Cell Death Discov. 2025;11:85. doi:10.1038/s41420-025-02368-1
- Xue Y, Hou X, Zhong Y, Zhang Y, Du S, et al. LNP-RNA-mediated antigen presentation leverages SARS-CoV-2-specific immunity for cancer treatment. Nat Commun. 2025;16:2198. doi:10.1038/s41467-025-57149-2
